PDSB
PDS BiotechnologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
PDS still has real clinical optionality: the April 2026 PDS01ADC publication showed encouraging early activity, and the lead HPV16 head-and-neck program already has a Phase 3 study with an amended design that could create a clearer regulatory shortcut if FDA feedback is constructive [#8-K-2026-04-15] [#10-K-2026-03-30].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Dilutive financing or unfavorable debt-related capital actions
Momentum
78
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.05 · Bull $2.40 · Bear $0.40
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum78 · Δ7d -
Value41 · Δ7d +0.1
Sentiment52 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
78
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
52
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 77.5 / Value 41.1 / Sentiment 51.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$63.63M
Beta
1.19
Shares Out
52.37M
P/E (TTM) · Derived
-1.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.61
Rev YoY
-
EPS YoY
+34.0%
Gross Margin
-
Op Margin
-
Net Debt
-$19.86M
Current Ratio
2.09
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology